PLA2G6 and metabolic dysfunction-associated steatotic liver disease: To evaluate the potential consequence of muscle-specific PLA2G6 expression on metabolic disease, we performed a similar association analysis with T2D (n = 180,834 cases vs. 1,159,055 controls)41, CVD (n = 181,522 cases vs. 1,165,690 controls)47, and NAFLD (n = 1483 cases vs. 17,781 controls)40.